BJR

Received: 09 June 2020 Revised: 21 September 2020 Accepted: 29 September 2020 ∞ 2021 The Authors. Published by the British Institute of Radiology

Cite this article as:

Hochhegger B, Zanon M, Altmayer S, Mandelli NS, Stüker G, Mohammed T-L, et al. COVID-19 mimics on chest CT: a pictorial review and radiologic guide. *Br J Radiol* 2020; **94**: 20200703.

PICTORIAL REVIEW

COVID-19 mimics on chest CT: a pictorial review and radiologic guide

^{1,2}BRUNO HOCHHEGGER, MD, PhD, ¹MATHEUS ZANON, MD, ²STEPHAN ALTMAYER, MD, ²NICOLE S MANDELLI, MD,
²GUILHERME STÜKER, MD, ³TAN-LUCIEN MOHAMMED, MD, ³NUPUR VERMA, MD,
⁴GUSTAVO SOUZA PORTES MEIRELLES, MD, PhD a

¹Graduate Program in Pathology, Federal University of Health Sciences of Porto Alegre - R. Sarmento Leite, Porto Alegre, Brazil 2Department of Radiology, Pontificia Universidade Catolica do Rio Grande do Sul, Porto Alegre, Brazil

³Department of Radiology, College of Medicine, University of Florida, Gainesville, FL, USA

4Department of Radiology, Fleury Group - R. Cincinato Braga, São Paulo, Brazil

5Department of Radiology, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil

Address correspondence to: Dr Bruno Hochhegger E-mail: *brunoho@ufcspa.edu.br*

ABSTRACT

Chest imaging is often used as a complementary tool in the evaluation of coronavirus disease 2019 (COVID-19) patients, helping physicians to augment their clinical suspicion. Despite not being diagnostic for COVID-19, chest CT may help clinicians to isolate high suspicion patients with suggestive imaging findings. However, COVID-19 findings on CT are also common to other pulmonary infections and non-infectious diseases, and radiologists and point-of-care physicians should be aware of possible mimickers. This state-of-the-art review goal is to summarize and illustrate possible etiologies that may have a similar pattern on chest CT as COVID-19. The review encompasses both infectious etiologies, such as non-COVID viral pneumonia, *Mycoplasma pneumoniae*, *Pneumocystis jiroveci*, and pulmonary granulomatous infectious, and non-infectious disorders, such as pulmonary embolism, fat embolism, cryptogenic organizing pneumonia, non-specific interstitial pneumonia, desquamative interstitial pneumonia, and acute and chronic eosinophilic pneumonia.

INTRODUCTION

The coronavirus disease 2019 (COVID-19) is a new type of coronavirus disease caused by SARS-CoV-2, which first emerged in Wuhan-China in December 2019. There was a significant spread worldwide, resulting in an increasing number of cases and deaths in the first half of 2020. By early June 2020, there were more than 6million confirmed cases around the world and almost 400,000 deaths caused by COVID-19, according to the World Health Organization (WHO). Just in the United States in the same timeline, approximately 1,8million individuals were infected, with more than [1](#page-6-0)00,000 deaths.¹

Most COVID-19 cases are asymptomatic or demonstrate mild symptoms, mostly presenting with upper respiratory tract symptoms such as sore throat, dry cough, headache, fatigue, and fever.² The disease may also begin with gastrointestinal symptoms, including diarrhea, nausea, and vomiting. In a smaller number of cases, patients can present with dyspnea, ventilatory disfunction, and respiratory failure. $3,4$ Older adults and patients with multiple comorbidities have a worse outcome, as they have a higher risk of developing diffuse alveolar damage requiring mechanical ventilation.⁴ Laboratory tests commonly show normal white blood cell or decreased lymphocyte count, as would be expected in viral infections.

Since COVID-19 has a high community transmission rate, it is essential to define the diagnosis in order to isolate infected patients and to monitor their outcome. Real-time reverse transcription polymerase chain reaction (rRT-PCR), a nucleic acid amplification test, is considered the gold-standard test for COVID-19 diagnosis.⁵ However, this test presents some limitations, such as unavailability in some countries and significant false-negative rates, mainly in the first days after the infection.^{[3,6](#page-6-2)}

Chest imaging has been used as a complementary tool in the evaluation of COVID-19 patients, including chest radiography, lung ultrasound, and chest CT scans. Despite not being definitively diagnostic for COVID-19, CT imaging can establish the presence of lung pathology and Figure 1. 51-year-old patient presenting with CT findings of COVID-19 confirmed by RT-PCR. (a) Axial chest CT in lung windows demonstrates bilateral predominantly peripheral ground-glass attenuation without consolidation. (b) Coronal reformatted CT shows bilateral ground-glass attenuation without a significant gradient. RT-PCR, reverse transcription polymerase chain reaction.

demonstrate findings deemed typical of COVID-19.^{[6](#page-6-5)} In this way, patients with suggestive symptoms and imaging of COVID-19 infection can be allocated to a holding room for contagious disease until RT-PCR test results become available. However, COVID-19 findings on CT can also overlap other viral infections and noninfectious etiologies, and radiologists and point-of-care physicians should be aware of possible mimickers.[7](#page-6-6)

This review aims to discuss the potential differential diagnoses of COVID-19 on chest CT and clarify the distinguishing clinical and radiological features.

COVID-19 TYPICAL CT FINDINGS

COVID-19 presentation on CT imaging will change according to the stage of the disease, which can be divided into early, intermediate, and late phases.⁷ Not all patients will go through all these imaging stages. Although some CT scans during the early phase

Figure 2. 58-year-old male with Influenza A H1N1 pneumonia. Axial CT image demonstrates a predominant pattern of consolidation with diffuse distribution, air bronchograms, and sparse ground-glass opacities.

of the disease (0–5 days after the onset of symptoms) may be normal, there is a predominance of small areas of ground-glass opacities (GGOs) with subpleural distribution in one or, most commonly, both lungs [\(Figure 1\)](#page-1-0). Less frequently, the chest CT may show a consolidation pattern.^{[7,8](#page-6-6)}

In the intermediate phase (about 6–11 days after the onset of symptoms), there is still a predominance of ground-glass pattern in most patients. However, there may be an expansion of CT findings in the pulmonary parenchyma with a higher number of GGO and bilateral involvement, as well as denser areas (foci of consolidation). $7,8$

In the late phase (about 12–17 days after the onset of symptoms), most patients have confluent lesions with mixed consolidation and GGO in a bilateral distribution. In association, there may also be inter- and intralobular septal thickening that manifests as a "crazy-paving" pattern.^{7,8} Less frequently, the "reversed halo sign" can also be seen in COVID-19, mainly in the intermediate to the late phase of the disease.^{7,8}

Some findings, such as atypical GGO distribution (sparing subpleural areas or unilateral), "tree-in-bud" pattern, moderate to severe pleural effusion, segmental or lobar consolidation without ground-glass opacities, diffuse nodules, mediastinal lymphadenopathy, pneumothorax, pneumomediastinum, and lung cavitation are rare findings in COVID-19. Those findings should raise a suspicion of other etiologies.

MIMICKERS OF TYPICAL CT FINDINGS IN COVID-19

Infectious etiologies that can mimic COVID-19 on CT.

Other viral pneumonia

Viral pathogens are one of most frequent etiology of pneumonia, accounting for around 25 and 70% of cases of community-acquired pneumonia in adults and children, respectively.^{[9](#page-6-7)} There are some characteristics which may help radiologists and clinicians to raise their suspicion of a specific virus. The disease pathogenesis, age group, and immune status can provide some clues on the diagnosis.^{10–12} However, there are several unspecific findings on CT scans, that may overlap with other lung conditions.

In this context, some viral infections tend to have some particular characteristics and show a predominant pattern on chest CT. In general, viral pneumonia presents as multifocal (random or segmental) findings with GGO and consolidations^{[10,12,13](#page-6-8)} [\(Figures 2 and 3\)](#page-1-1). A recent meta-analysis with 2263 patients reported overlapping CT findings between COVID-19 and other viral pneumonia, including high prevalences of a mixed pattern of GGO and consolidation, bilateral distribution, and involvement of lower lobes.¹³ On the other hand, COVID-19 pneumonia presented a higher prevalence of peripheral distribution, and involvement of upper and middle lobes when compared to other viral pneumonia.^{[13](#page-6-9)}

Although rare in COVID-19, bronchial wall thickening, and pleural effusion are common findings in infections by adenovirus,

Figure 3. 67-year-old male with adenovirus pneumonia. (a, b) Axial CT images demonstrate areas of consolidation with peripheral distribution, lower lobe predominance, and interlobular septal thickening.

parvovirus, paramyxovirus (measles), herpes (HSV), hantavirus, and phenuivirus.¹² Hantaviruses infections and COVID-19 may have a shared CT finding as interlobular septal thickening. Pulmonary micronodules and larger nodules are predominantly seen in adenoviruses, herpes (Herpes virus and varicella-zoster), paramyxovirus (measles), pneumovirus, and orthomyxovirus, and are uncommon in COVID-19 patients.^{[12](#page-6-10)}

Mycoplasma pneumoniae *infection*

Mycoplasma pneumoniae is a frequent cause of pneumonia, especially in children and young adults. However, it may affect all ages, regardless of the patient's immune status. Pneumonia is the most common clinical manifestation in school-aged children, and common symptoms include fever, non-productive cough, fatigue, dyspnea, headache, and sore throat.¹⁴ In a study with more than 2200 children hospitalized with radiographically confirmed community-acquired pneumonia in the United States, *M. pneumoniae* was the most prevalent bacterial pathogen, affecting around 8% of cases.^{[9](#page-6-7)} In adults, upper respiratory tract symptoms and acute bronchitis are the most common syndromes, while *M. pneumoniae* pneumonia is less common, affecting from 2 to 12% of adults with community-acquired pneumonia.^{[9](#page-6-7)}

Figure 4. 48-year-old female with non-Hodgkin lymphoma and *Mycoplasma pneumoniae* infection. (a–d) Axial CT images demonstrate random centrilobular nodules with ground-glass and solid attenuation, bronchial wall thickening and consolidations predominantly in the lower lobes.

Figure 5. 32-year-old male with acquired immunodeficiency syndrome and *Pneumocystis jiroveci* pneumonia. (a, b) Axial CT images demonstrate ground-glass opacities and intralobular septal thickening in the periphery of the upper lobes and the superior segments of the lower lobes.

Typical CT findings include bronchial wall thickening and centrilobular nodules, as well as GGO and consolidations, commonly affecting more than one lobe [\(Figure 4](#page-2-0)). Less frequently, it demonstrates reticular or linear opacities, lymphadenopathy, and pleural effusion.^{[15](#page-6-12)} Centrilobular nodules and bronchial wall thickening are commonly seen in *Mycoplasma pneumonia*e infections but are uncommon in COVID-19. The presence of such findings could help to differentiate *M. pneumoniae* and COVID-19, as the clinical presentation of both diseases might overlap.

Pulmonary Pneumocystis jiroveci *infection*

Pneumocystis jiroveci pneumonia (PJP) is an opportunistic disease usually affecting immunocompromised patients with CD4 lymphocyte counts lower than 200 cells mm− ³ and especially under 100 cells mm[−] ³. There are few patients (around 10–15%) with CD4 lymphocyte count above 200 cells mm− ³ presenting PJP.^{[16](#page-6-13)} Despite being historically associated with HIVinfected patients, PJP can also occur in HIV-uninfected patients with immunosuppression due to malignancies, organ transplant, or autoimmune diseases. Incidence rates of PJP between HIV-infected patients are around 3.9 to 7.7 per 100,000 person-years.^{[17](#page-6-14)}

When immunosuppression is known, there is a higher chance of distinguishing PJP from COVID-19, although CT scans may be similar. Sometimes immunocompromised patients may be first aware of their diagnosis due to respiratory symptoms onset as a result of pulmonary pneumocystis infection. While COVID-19 has a CT predominance of multifocal and peripheral GGOs, the main pattern of PJP is represented as a central and diffuse distri-bution with relative subpleural sparing [\(Figure 5](#page-2-1)).^{[16](#page-6-13)} Both conditions can present with some degree of consolidations, interlobular septal thickening, and "crazy paving pattern". Around one-third of PJP cases present pulmonary cysts with variable shape, wall thickness, and size, 16 findings that have not been reported in COVID-19. Nodules and tree-in-bud opacities are uncommon in both PJP and COVID-19.⁶

Infectious pulmonary granulomatous disease

There are a considerable number of etiologies for granulomatous pulmonary disease, both infectious or noninfectious, and therefore chest CT scans can show different patterns of presenta-tion.^{[18](#page-6-15)} Some of these findings are commonly seen in COVID-19 CT scans and may confound radiologists and clinicians in

Figure 6. 58-year-old male with paracoccidioidomycosis**.** (a–c) Axial and (d) coronal CT images demonstrate diffuse ground-glass lesions in a random distribution, some with a peripheral rim of consolidation yielding the reversed halo sign and some solid nodules.

determining the correct diagnosis. As demonstrated in COVID-19, CT finding in granulomatous diseases include GGOs, especially in paracoccidioidomycosis [\(Figure 6](#page-3-0)). A reversed halo sign may also be present in tuberculosis, among others.¹⁸ Clinical, laboratory and immune status details are indispensable for investigating the etiology in order to differentiate from COVID-19.

Non-infectious etiologies that can mimic COVID-19 on CT

Pulmonary embolism

CT pulmonary angiography (CTPA) is one of the most accurate methods for the diagnosis of pulmonary embolism (PE) .^{[19](#page-6-16)} The diagnostic criteria for acute PE include the direct visualization of the emboli causing arterial occlusion with failure to enhance the entire lumen due to a filling defect.^{19,20} Pulmonary infarct due to acute PE can present on CTPA as wedge-shaped peripheral lung opacities, often with central ground glass and a rim of consolidation: the reversed halo sign^{[18,19,21](#page-6-15)} [\(Figure 7\)](#page-3-1). In COVID-19, the reversed halo sign is uncommon, found in only 4% of patients in the late phase in one study.⁸ Therefore, when this sign is present, pulmonary infarct should be included in the differential diagnosis.

Nevertheless, the association of PE and COVID-19 appears to be common, with an incidence in CT angiography scans of COVID-19 patients ranging from 22 to 30% .²²⁻²⁴ Before the COVID-19 pandemics, respiratory viruses had already been associated with procoagulant activity in human endothelial cells.^{[25](#page-7-0)} Likewise, the SARS-CoV-2 has also been associated with thrombotic events in macro- and micro-circulation. Severe stages of COVID-19 may induce a proinflammatory and hypercoagu-lable state, which could increase the risk of PE development.^{[26](#page-7-1)}

In patients with a clinical suspicion of COVID-19 infection, presence of additional findings in non-enhanced CT scans such as dilatation of pulmonary trunk, enlargement of the right cardiac chamber, and presence of pleural effusion could indicate the concomitant presence of $PE²⁷$ Likewise, some clinical parameters, such as high D-dimer levels, hemoptysis, and sudden worsening of respiratory function or chest pain, should also be considered.[27](#page-7-2) When these other findings are present, complementing the investigation with a CTPA scan may be helpful.

Fat embolism

Fat embolism usually occurs as a rare complication of long bone fracture with a prevalence of 1–3% of patients with tibial or femoral fractures and 20% in more severe osseous polytrauma.^{[28](#page-7-3)} The classical clinical triad consists of respiratory distress, cerebral abnormalities, and petechial hemorrhages. Pulmonary fat embolism can present at CT as areas of GGO with interlobular septal thickening, ground-glass changes with patchy distribution resulting in a geographic appearance, or as nodular opac-ities without any zone predominance^{[29](#page-7-4)} (Figure 8). Therefore, some CT findings may overlap with COVID-19 presentation. However, the clinical history of recent long bone fracture, trauma, or surgical fixation can assist the differentiation, and the use of Gurd's and Wilson's criteria for fat embolism syndrome might be helpful.^{[30](#page-7-5)}

Non-infectious organizing pneumonia

The organizing pneumonia pattern is the imaging representation of a healing process. Pathology shows loose plugs of connective tissue in airspaces and distal airways, sometimes progressing

Figure 7. 48-year-old male with pulmonary embolism**.** (a) Axial CT image demonstrate a wedge-shaped peripheral lung opacity in the right lower lobe with a ground-glass core and a peripheral rim of consolidation yielding the reversed halo sign. (b) CT angiography evidencing the thrombus in the right interlobar artery.

Figure 8. 27-year-old male victim of a motorcycle accident with multiples injuries and developed respiratory distress a couple of days after the trauma due to fat embolism. (a) Three-dimensional rendering reconstruction of CT images demonstrates tibial and fibular fracture. (b) Axial CT image and (c) coronal maximum intensity projection reconstruction demonstrate patchy groundglass opacities in the lower lobes with subpleural sparing.

with filled bronchial endoluminal spaces by granulation material, known as Masson bodies.[31,32](#page-7-6) There may also be interstitial inflammatory involvement.

Cryptogenic organizing pneumonia is an interstitial lung disease that represents the idiopathic form of this CT pattern. The reported annual incidence varies from 1.1 to 7 cases per 100,000 hospital admissions.^{21,33} Patients are usually between 50 and 60 years old, equally affecting males and females. They may present with subacute symptoms, such as cough, mild dyspnea, fever, malaise, and sometimes weight loss.^{[34,35](#page-7-7)} Therefore, the assessment of clinical and epidemiological presentation and progression is essential for differential diagnoses.

CT imaging is mostly polymorphic, characterized by a mixed pattern of consolidation and GGO, that may be single or multiple, with a focal, bronchocentric, or subpleural distribution (Figure 9). 31 Moreover, there may be a nodular or crazy paving pattern and reversed halo sign. Due to its several forms of presentation, organizing pneumonia may have a considerable number of differential diagnoses other than infections, such as drug toxicity, immune diseases, actinic lesions, among others [\(Figure 10](#page-4-2)).

Non-specific interstitial pneumonia

Non-specific interstitial pneumonia (NSIP) is one of the most common interstitial lung disease patterns in chest CT. NSIP is usually associated with connective tissue diseases (CTD), such as systemic sclerosis, Sjögren syndrome, polymyositis, and dermatomyositis. NSIP can also be due to HIV infection or be idiopathic. $34,36$ Clinical history commonly includes dyspnea and cough that develop subacutely over weeks to months.^{[36](#page-7-8)} About one-third of cases present fever or flu-like symptoms. NSIP associated with CTD has a similar distribution between males and females, while idiopathic NSIP affects more middle-aged females who are never smokers.^{[37](#page-7-9)}

Chest CT often demonstrates a subpleural, bilateral, and lower lobe predominance of ground glass with or without reticular abnormalities and mild subpleural fibrosis [\(Figure 11](#page-5-0)). Therefore, the ground-glass component can be considered an alternative diagnosis for COVID-19. 38 However, the ground glass areas are less geographic, and there are nearly always some component of subpleural fibrotic findings, such as subpleural reticulation, with fibrotic subtype also having traction bronchiectasis and volume loss of the affected lobe. Likewise, clinical symptoms, the time course of the disease symptoms, and other associated underlying conditions can guide the diagnosis. Identifying this non-acute lung differential diagnosis is essential as these patients do need outpatient follow-up at an appropriate time to have full

Figure 9. 57-year-old female with cryptogenic organizing pneumonia. (a) Axial and (b) coronal CT images shows bilateral perilobular opacities, interlobular septal thickening, and the reversed halo sign (arrow).

Figure 10. 61-year-old male with amiodarone-induced organizing pneumonia. (a, b) Axial CT images with peripheral and bilateral areas of ground-glass lesions in random distribution and with some reticular opacities.

COVID-19 mimics on chest CT

Figure 11. 49-year-old female with non-specific interstitial pneumonia. (a–c) Axial and (d) coronal CT images demonstrate reticulations in the subpleural zones, predominantly in the lower lobes, with some ground-glass opacities and bronchiectasis.

workup to confirm the diagnosis and medication management to reduce lung involvement and symptoms.

Desquamative interstitial pneumonia

Desquamative interstitial pneumonia (DIP) is seen predominantly in smokers, with few additional conditions associated with its presentation such as autoimmune diseases and HIV. In pathology analysis, there is an interstitial reaction caused by the tobacco, showed by pigmented macrophages conglomerates in the alveoli and various degrees of interstitial fibrosis.³⁴ DIP is rare, occurring in less than 1% of ILD. More than 90% of patients are smokers, in their fourth and fifth decades, in a 2:1 male to female ratio with insidious onset symptoms, such as dry cough and dyspnea.^{[39,40](#page-7-11)}

Chest CT shows subpleural and bilateral ground-glass opacities frequently associated with irregular linear opacities predomi-nantly involving the lower lobes³⁴ ([Figure 12](#page-5-1)). Due to the peripheral, diffuse, and bilateral involvement of pulmonary parenchyma in chest CT, generally with GGO, desquamative interstitial pneumonia may also be considered a COVID-19 differential diagnosis in early stages, even though, as other pathologies, the disease's course and tobacco use can help in the diagnosis.

Figure 13. 40-year-old male with acute eosinophilic pneumonia. Axial CT demonstrates bilateral and peripheral groundglass opacites with interlobular septal thickening.

Acute and chronic eosinophilic pneumonia

Eosinophilic lung diseases are a heterogeneous group of disorders marked by lung opacities with tissue or peripheral eosinophilia. The diagnosis of eosinophilic lung disease can be made when the following features are encountered: (1) pulmonary opacities with peripheral eosinophilia, (2) tissue eosinophilia confirmed at lung biopsy, or (3) increased eosinophils in bronchoalveolar lavage fluid. 41 Regarding the disease onset, they can be divided into acute and chronic eosinophilic pneumonia.

In the acute form, patients present with acute/subacute onset of fever and hypoxemia. The exact prevalence is unknown, and some series reported an incidence of 9.1 per 100,000 person-years.^{[42](#page-7-13)} All age groups can be affected, with an average of 30 years. Tobacco smoking is the most frequently implicated trigger. Males and females equally affected. On chest CT imaging, acute EP present patchy areas of GGO accompanied by consolidation opacities and smooth interlobular septal thickening ([Figure 13\)](#page-5-2), findings that overlap with COVID-19 pneumonia.^{[41](#page-7-12)} Thickening of bronchovascular bundles, lymph node enlargement, and pleural effusions are also common findings.

On the other hand, patients with chronic eosinophilic pneumonia present with an insidious onset of symptoms and show not only bronchoalveolar lavage fluid eosinophilia but also peripheral

Figure 12. 44-year-old male, smoker, with desquamative interstitial pneumonia. (a–c) Axial CT images demonstrate ground-glass and reticular opacities in the periphery of the lower lobes and the middle lobe.

eosinophilia and frequently increased IgE serum levels.⁴¹ Chest CT in chronic eosinophilic pneumonia mostly demonstrates nonsegmental areas of airspace consolidation with peripheral predominance. GGO, nodules, reticulation, and pleural effusions are rare findings in the chronic phase.^{[41](#page-7-12)}

CONCLUSION

Due to COVID-19 high infectivity rates and the significant spread around the world in early 2020, it is essential not only to prepare health-care systems in order to manage all infected patients but also to conclude the right diagnosis. The latter will reduce acute

care burden when diseases are identified as chronic or guide alternative management in other acute infections. Despite not being diagnostic for COVID-19, CT may help clinicians to isolate high suspicion patients with suggestive image findings. There is a large number of differential diagnoses for COVID-19 on chest CT scans, and clinicians and radiologists must be aware of these conditions. The careful consideration of acuity of symptoms and patient history with the knowledge of chest CT patterns in COVID-19 and its primary clinical confounders is indispensable for making the right diagnosis.

REFERENCES

- 1. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard 2020. 2020. Available from: <https://covid19.who.int/>.
- 2. Rubin GD, Ryerson CJ, Haramati LB, Sverzellati N, Kanne JP, Raoof S, et al. The role of chest imaging in patient management during the COVID-19 pandemic: a multinational consensus statement from the Fleischner Society. *Chest* 2020; **158**: 106–16. doi: [https://doi.org/10.1016/j.chest.2020.04.](https://doi.org/10.1016/j.chest.2020.04.003) [003](https://doi.org/10.1016/j.chest.2020.04.003)
- 3. Zu ZY, Jiang MD, Xu PP, Chen W, Ni QQ, Lu GM, et al. Coronavirus disease 2019 (COVID-19): a perspective from China. *Radiology* 2020; **296**: E15–25. doi: [https://doi.](https://doi.org/10.1148/radiol.2020200490) [org/10.1148/radiol.2020200490](https://doi.org/10.1148/radiol.2020200490)
- 4. Ding X, Xu J, Zhou J, Long Q. Chest CT findings of COVID-19 pneumonia by duration of symptoms. *Eur J Radiol* 2020; **127**: 109009. doi: [https://doi.org/10.1016/j.](https://doi.org/10.1016/j.ejrad.2020.109009) [ejrad.2020.109009](https://doi.org/10.1016/j.ejrad.2020.109009)
- 5. World Health Organization.Laboratory testing of 2019 novel coronavirus (2019 nCoV) in suspected human cases: interim guidance, 17 January 2020. 2020. Available from: [https://apps.who.int/iris/handle/10665/](https://apps.who.int/iris/handle/10665/330676) [330676](https://apps.who.int/iris/handle/10665/330676).
- 6. Dai W-C, Zhang H-W, Yu J, Xu H-J, Chen H, Luo S-P, et al. Ct imaging and differential diagnosis of COVID-19. *Can Assoc Radiol J* 2020; **71**: 195–200. doi: [https://doi.org/10.](https://doi.org/10.1177/0846537120913033) [1177/0846537120913033](https://doi.org/10.1177/0846537120913033)
- 7. Li M, Lei P, Zeng B, Li Z, Yu P, Fan B, et al. Coronavirus disease (COVID-19): spectrum of CT findings and temporal progression of the disease. *Acad Radiol* 2020; **27**: 603–8. doi: <https://doi.org/10.1016/j.acra.2020.03.003>
- 8. Simpson S, Kay FU, Abbara S, Bhalla S, Chung JH, Chung M, et al. Radiological society of north America expert consensus statement on reporting chest CT findings related to COVID-19. Endorsed by the society of Thoracic Radiology, the American

college of Radiology, and RSNA - secondary publication. *J Thorac Imaging* 2020; **35**: 219–27. doi: [https://doi.org/10.1097/RTI.](https://doi.org/10.1097/RTI.0000000000000524) [0000000000000524](https://doi.org/10.1097/RTI.0000000000000524)

- 9. Jain S, Williams DJ, Arnold SR, Ampofo K, Bramley AM, Reed C, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. *N Engl J Med* 2015; **372**: 835–45. doi: [https://doi.org/](https://doi.org/10.1056/NEJMoa1405870) [10.1056/NEJMoa1405870](https://doi.org/10.1056/NEJMoa1405870)
- 10. Koo HJ, Lim S, Choe J, Choi S-H, Sung H, Do K-H. Radiographic and CT features of viral pneumonia. *Radiographics* 2018; **38**: 719–39. doi: [https://doi.org/10.1148/rg.](https://doi.org/10.1148/rg.2018170048) [2018170048](https://doi.org/10.1148/rg.2018170048)
- 11. Kim EA, Lee KS, Primack SL, Yoon HK, Byun HS, Kim TS, et al. Viral pneumonias in adults: radiologic and pathologic findings. *Radiographics* 2002; **22 Spec No**(suppl_1): S137–49. doi: [https://doi.org/10.1148/](https://doi.org/10.1148/radiographics.22.suppl_1.g02oc15s137) [radiographics.22.suppl_1.g02oc15s137](https://doi.org/10.1148/radiographics.22.suppl_1.g02oc15s137)
- 12. Franquet T. Imaging of pulmonary viral pneumonia. *Radiology* 2011; **260**: 18–39. doi: <https://doi.org/10.1148/radiol.11092149>
- 13. Altmayer S, Zanon M, Pacini GS, Watte G, Barros MC, Mohammed T-L, et al. Comparison of the computed tomography findings in COVID-19 and other viral pneumonia in immunocompetent adults: a systematic review and meta-analysis. *Eur Radiol* 2020; **0**: 1–12. doi: [https://doi.org/10.](https://doi.org/10.1007/s00330-020-07018-x) [1007/s00330-020-07018-x](https://doi.org/10.1007/s00330-020-07018-x)
- 14. Gordon O, Oster Y, Michael-Gayego A, Marans RS, Averbuch D, Engelhard D, et al. The clinical presentation of pediatric Mycoplasma pneumoniae Infections-A single center cohort. *Pediatr Infect Dis J* 2019; **38**: 698–705. doi: [https://doi.org/10.1097/INF.](https://doi.org/10.1097/INF.0000000000002291) [0000000000002291](https://doi.org/10.1097/INF.0000000000002291)
- 15. Miyashita N, Sugiu T, Kawai Y, Oda K, Yamaguchi T, Ouchi K, et al. Radiographic features of Mycoplasma pneumoniae pneumonia: differential diagnosis and performance timing. *BMC Med Imaging*

2009; **9**: 7. doi: [https://doi.org/10.1186/1471-](https://doi.org/10.1186/1471-2342-9-7) [2342-9-7](https://doi.org/10.1186/1471-2342-9-7)

- 16. Kanne JP, Yandow DR, Meyer CA. Pneumocystis jiroveci pneumonia: highresolution CT findings in patients with and without HIV infection. *AJR Am J Roentgenol* 2012; **198**: W555–61. doi: [https://doi.org/10.](https://doi.org/10.2214/AJR.11.7329) [2214/AJR.11.7329](https://doi.org/10.2214/AJR.11.7329)
- 17. Solano L MF, Alvarez Lerma F, Grau S, Segura C, Aguilar A. Pneumocystis jiroveci pneumonia: clinical characteristics and mortality risk factors in an intensive care unit. *Med Intensiva* 2015; **39**: 13–19. doi: <https://doi.org/10.1016/j.medin.2013.11.006>
- 18. Marchiori E, Zanetti G, Meirelles GSP, Escuissato DL, Souza AS, Hochhegger B. The reversed halo sign on high-resolution CT in infectious and noninfectious pulmonary diseases. *AJR Am J Roentgenol* 2011; **197**: W69–75. doi: [https://doi.org/10.2214/AJR.](https://doi.org/10.2214/AJR.10.5762) [10.5762](https://doi.org/10.2214/AJR.10.5762)
- 19. Stein PD, Fowler SE, Goodman LR, Gottschalk A, Hales CA, Hull RD, et al. Multidetector computed tomography for acute pulmonary embolism. *N Engl J Med* 2006; **354**: 2317–27. doi: [https://doi.org/10.](https://doi.org/10.1056/NEJMoa052367) [1056/NEJMoa052367](https://doi.org/10.1056/NEJMoa052367)
- 20. Souza LVS, Zanon M, Souza AS, Irion K, Penha D, Alves GRT, et al. "Pulmonary vein sign" for pulmonary embolism diagnosis in computed tomography angiography. *Lung* 2017; **195**: 769–74. doi: [https://doi.org/10.](https://doi.org/10.1007/s00408-017-0057-7) [1007/s00408-017-0057-7](https://doi.org/10.1007/s00408-017-0057-7)
- 21. Gudmundsson G, Sveinsson O, Isaksson HJ, Jonsson S, Frodadottir H, Aspelund T. Epidemiology of organising pneumonia in Iceland. *Thorax* 2006; **61**: 805–8. doi: [https://](https://doi.org/10.1136/thx.2006.059469) doi.org/10.1136/thx.2006.059469
- 22. Grillet F, Behr J, Calame P, Aubry S, Delabrousse E. Acute pulmonary embolism associated with COVID-19 pneumonia detected with pulmonary CT angiography. *Radiology* 2020; **296**: E186–8. doi: [https://doi.](https://doi.org/10.1148/radiol.2020201544) [org/10.1148/radiol.2020201544](https://doi.org/10.1148/radiol.2020201544)
- 23. Leonard-Lorant I, Delabranche X, Severac F, Helms J, Pauzet C, Collange O, et al. Acute pulmonary embolism in COVID-19 patients on CT angiography and relationship to Ddimer levels. *Radiology* 2020; **201561**.
- 24. Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? *Eur Heart J* 2020; **41**: 1858. doi: [https://doi.org/10.1093/](https://doi.org/10.1093/eurheartj/ehaa254) [eurheartj/ehaa254](https://doi.org/10.1093/eurheartj/ehaa254)
- 25. Visseren FL, Bouwman JJ, Bouter KP, Diepersloot RJ, de Groot PH, Erkelens DW. Procoagulant activity of endothelial cells after infection with respiratory viruses. *Thromb Haemost* 2000; **84**: 319–24.
- 26. Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. *J Thromb Haemost* 2020; **18**: 1559–61. doi: [https://doi.](https://doi.org/10.1111/jth.14849) [org/10.1111/jth.14849](https://doi.org/10.1111/jth.14849)
- 27. Moreira BL, Santana PRP, Zanetti G, Marchiori E. COVID-19 and acute pulmonary embolism: what should be considered to indicate a computed tomography pulmonary angiography scan? *Rev Soc Bras Med Trop* 2020; **53**: e20200267. doi: [https://doi.org/10.1590/0037-8682-0267-](https://doi.org/10.1590/0037-8682-0267-2020) [2020](https://doi.org/10.1590/0037-8682-0267-2020)
- 28. Fukumoto LE, Fukumoto KD. Fat embolism syndrome. *Nurs Clin North Am* 2018; **53**: 335–47. doi: [https://doi.org/10.1016/j.cnur.](https://doi.org/10.1016/j.cnur.2018.04.003) [2018.04.003](https://doi.org/10.1016/j.cnur.2018.04.003)
- 29. Malagari K, Economopoulos N, Stoupis C, Daniil Z, Papiris S, Müller NL, et al. High-Resolution CT findings in mild pulmonary fat embolism. *Chest* 2003; **123**: 1196–201. doi: [https://doi.org/10.1378/chest.123.4.](https://doi.org/10.1378/chest.123.4.1196) [1196](https://doi.org/10.1378/chest.123.4.1196)
- 30. Kwiatt ME, Seamon MJ. Fat embolism syndrome. *Int J Crit Illn Inj Sci* 2013; **3**: 64. doi: [https://doi.org/10.4103/2229-5151.](https://doi.org/10.4103/2229-5151.109426) [109426](https://doi.org/10.4103/2229-5151.109426)
- 31. Hansell DM, Bankier AA, MacMahon H, McLoud TC, Müller NL, Remy J. Fleischner Society: glossary of terms for thoracic imaging. *Radiology* 2008; **246**: 697–722. doi: [https://doi.org/10.1148/radiol.](https://doi.org/10.1148/radiol.2462070712) [2462070712](https://doi.org/10.1148/radiol.2462070712)
- 32. Baque-Juston M, Pellegrin A, Leroy S, Marquette CH, Padovani B. Organizing pneumonia: what is it? A conceptual approach and pictorial review. *Diagn Interv Imaging* 2014; **95**: 771–7. doi: [https://doi.org/](https://doi.org/10.1016/j.diii.2014.01.004) [10.1016/j.diii.2014.01.004](https://doi.org/10.1016/j.diii.2014.01.004)
- 33. Alasaly K, Müller N, Ostrow DN, Champion P, FitzGerald JM. Cryptogenic organizing pneumonia. A report of 25 cases and a review of the literature. *Medicine* 1995; **74**: 201–11. doi: [https://doi.org/10.1097/](https://doi.org/10.1097/00005792-199507000-00004) [00005792-199507000-00004](https://doi.org/10.1097/00005792-199507000-00004)
- 34. Mueller-Mang C, Grosse C, Schmid K, Stiebellehner L, Bankier AA. What every radiologist should know about idiopathic interstitial pneumonias. *Radiographics* 2007; **27**: 595–615. doi: [https://doi.org/10.1148/rg.](https://doi.org/10.1148/rg.273065130) [273065130](https://doi.org/10.1148/rg.273065130)
- 35. Lee JW, Lee KS, Lee HY, Chung MP, Yi CA, Kim TS, et al. Cryptogenic organizing pneumonia: serial high-resolution CT findings in 22 patients. *AJR Am J Roentgenol* 2010; **195**: 916–22. doi: [https://doi.org/10.](https://doi.org/10.2214/AJR.09.3940) [2214/AJR.09.3940](https://doi.org/10.2214/AJR.09.3940)
- 36. Kligerman SJ, Groshong S, Brown KK, Lynch DA. Nonspecific interstitial pneumonia: radiologic, clinical, and pathologic considerations. *Radiographics* 2009; **29**:

73–87. doi: [https://doi.org/10.1148/rg.](https://doi.org/10.1148/rg.291085096) [291085096](https://doi.org/10.1148/rg.291085096)

- 37. Travis WD, Hunninghake G, King TE, Lynch DA, Colby TV, Galvin JR, et al. Idiopathic nonspecific interstitial pneumonia: report of an American thoracic Society project. *Am J Respir Crit Care Med* 2008; **177**: 1338–47. doi: [https://doi.org/10.1164/rccm.200611-](https://doi.org/10.1164/rccm.200611-1685OC) [1685OC](https://doi.org/10.1164/rccm.200611-1685OC)
- 38. Hani C, Trieu NH, Saab I, Dangeard S, Bennani S, Chassagnon G, et al. COVID-19 pneumonia: a review of typical CT findings and differential diagnosis. *Diagn Interv Imaging* 2020; **101**: 263–8. doi: [https://doi.](https://doi.org/10.1016/j.diii.2020.03.014) [org/10.1016/j.diii.2020.03.014](https://doi.org/10.1016/j.diii.2020.03.014)
- 39. Godbert B, Wissler M-P, Vignaud J-M. Desquamative interstitial pneumonia: an analytic review with an emphasis on aetiology. *Eur Respir Rev* 2013; **22**: 117–23. doi: [https://doi.org/10.1183/09059180.](https://doi.org/10.1183/09059180.00005812) [00005812](https://doi.org/10.1183/09059180.00005812)
- 40. Attili AK, Kazerooni EA, Gross BH, Flaherty KR, Myers JL, Martinez FJ. Smoking-related interstitial lung disease: radiologic-clinicalpathologic correlation. *Radiographics* 2008; **28**: 1383–96. doi: [https://doi.org/10.1148/rg.](https://doi.org/10.1148/rg.285075223) [285075223](https://doi.org/10.1148/rg.285075223)
- 41. Jeong YJ, Kim K-I, Seo IJ, Lee CH, Lee KN, Kim KN, et al. Eosinophilic lung diseases: a clinical, radiologic, and pathologic overview. *Radiographics* 2007; **27**: 617–37. doi: [https://](https://doi.org/10.1148/rg.273065051) doi.org/10.1148/rg.273065051
- 42. Shorr AF, Scoville SL, Cersovsky SB, Shanks GD, Ockenhouse CF, Smoak BL, et al. Acute eosinophilic pneumonia among US military personnel deployed in or near Iraq. *JAMA* 2004; **292**: 2997–3005. doi: [https://doi.org/](https://doi.org/10.1001/jama.292.24.2997) [10.1001/jama.292.24.2997](https://doi.org/10.1001/jama.292.24.2997)